Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
THLD's Cash to Debt is ranked higher than
94% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 49.03 vs. THLD: No Debt )
Ranked among companies with meaningful Cash to Debt only.
THLD' s Cash to Debt Range Over the Past 10 Years
Min: 17.14  Med: No Debt Max: No Debt
Current: No Debt
Interest Coverage No Debt
THLD's Interest Coverage is ranked higher than
94% of the 464 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. THLD: No Debt )
Ranked among companies with meaningful Interest Coverage only.
THLD' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
F-Score: 6
Z-Score: -1.51
M-Score: 8.35
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 42.77
THLD's Operating margin (%) is ranked higher than
95% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -82.26 vs. THLD: 42.77 )
Ranked among companies with meaningful Operating margin (%) only.
THLD' s Operating margin (%) Range Over the Past 10 Years
Min: -48445.16  Med: -820.92 Max: 42.77
Current: 42.77
-48445.16
42.77
Net-margin (%) 66.32
THLD's Net-margin (%) is ranked higher than
98% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -80.77 vs. THLD: 66.32 )
Ranked among companies with meaningful Net-margin (%) only.
THLD' s Net-margin (%) Range Over the Past 10 Years
Min: -41375.81  Med: -1241.37 Max: 66.32
Current: 66.32
-41375.81
66.32
ROE (%) 535.65
THLD's ROE (%) is ranked higher than
100% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. THLD: 535.65 )
Ranked among companies with meaningful ROE (%) only.
THLD' s ROE (%) Range Over the Past 10 Years
Min: -544.3  Med: -96.09 Max: 535.65
Current: 535.65
-544.3
535.65
ROA (%) 90.37
THLD's ROA (%) is ranked higher than
99% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: -26.97 vs. THLD: 90.37 )
Ranked among companies with meaningful ROA (%) only.
THLD' s ROA (%) Range Over the Past 10 Years
Min: -132.78  Med: -67.3 Max: 90.37
Current: 90.37
-132.78
90.37
ROC (Joel Greenblatt) (%) 9607.98
THLD's ROC (Joel Greenblatt) (%) is ranked higher than
100% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -366.92 vs. THLD: 9607.98 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
THLD' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -7379.85  Med: -2750.54 Max: 9607.98
Current: 9607.98
-7379.85
9607.98
Revenue Growth (3Y)(%) 113.20
THLD's Revenue Growth (3Y)(%) is ranked higher than
95% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. THLD: 113.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
THLD' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -100 Max: 514.5
Current: 113.2
0
514.5
» THLD's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-02)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

THLD Guru Trades in Q3 2015

Jim Simons 454,200 sh (+7.60%)
First Eagle Investment 500,000 sh (-60.65%)
» More
Q4 2015

THLD Guru Trades in Q4 2015

Jim Simons 653,664 sh (+43.92%)
First Eagle Investment Sold Out
» More
Q1 2016

THLD Guru Trades in Q1 2016

Jim Simons 1,016,764 sh (+55.55%)
» More
Q2 2016

THLD Guru Trades in Q2 2016

First Eagle Investment 3,199,433 sh (New)
Jim Simons 774,763 sh (-23.80%)
» More
» Details

Insider Trades

Latest Guru Trades with THLD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:TTHI, OTCPK:DYAI, AMEX:PLX, OTCPK:OGRMF, OTCPK:PRTX, NAS:MTP, NAS:NVET, NAS:TRIL, NAS:CALA, OTCPK:INNMF, AMEX:IBIO, NAS:PBMD, NAS:CAPR, NAS:DMPI, NAS:MBRX, NAS:CASI, AMEX:CRMD, NAS:CHMA, NAS:DNAI, NAS:BUR » details
Traded in other countries:NZW1.Germany,
Threshold Pharmaceuticals Inc is a biotechnology company. It is engaged in discovery and development of drugs targeting the microenvironment of solid tumors as novel treatments for patients living with cancer.

Threshold Pharmaceuticals Inc is a Delaware corporation incorporated on October 17, 2001. It's a biotechnology company focused on the discovery and development of drugs targeting the microenvironment of solid tumors as novel treatments for patients living with cancer. The microenvironment of these tissues is characterized by hypoxia or lack of oxygen. Its hypoxia activated prodrug ("HAP") product candidates, including TH-302, are designed to specifically target the hypoxic microenvironment of tumors by selective activation of the prodrug to release a potent cytotoxin. Its focus is on product candidates for the treatment of patients with cancer. Its clinical development efforts are currently engaged in TH-302, for which it entered a license and co-development agreement with Merck KGaA for development and commercialization. TH-302 is a novel drug candidate that is activated under severe hypoxic conditions and was designed to specifically target the severe hypoxic regions that are believed to be present in all solid tumors and hematologic malignancies. The production of TH-302 employs small molecule organic chemistry procedures that are standard for the pharmaceutical industry. It currently relies on contract manufacturers for the manufacture of active pharmaceutical ingredient ("API"), and final drug product of TH-302. Under its license and co-development agreement with Merck KGaA, the Company is dependent on Merck for clinical and commercial supply of TH-302, except for clinical trials for United States approval of TH-302 for soft tissue sarcoma and for any other clinical trials for which it is responsible. For these latter cases, it can obtain clinical supply directly from existing or new suppliers. It currently uses contract manufacturers to manufacture TH-302 API and TH-302 drug product. The commercial sale for pancreatic cancer, TH-302 would compete with Gemzar, marketed by Eli Lilly and Company; Tarceva, marketed by Genentech and Astellas Oncology; Abraxane marketed by Celgene; and FOLFIRINOX. The manufacturing and marketing of its potential products and its ongoing research and development activities are subject to extensive regulation by the FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries.

Ratios

vs
industry
vs
history
P/E(ttm) 1.45
THLD's P/E(ttm) is ranked higher than
95% of the 237 Companies
in the Global Biotechnology industry.

( Industry Median: 28.72 vs. THLD: 1.45 )
Ranked among companies with meaningful P/E(ttm) only.
THLD' s P/E(ttm) Range Over the Past 10 Years
Min: 0.45  Med: 2.5 Max: 55.56
Current: 1.45
0.45
55.56
PE(NRI) 1.45
THLD's PE(NRI) is ranked higher than
97% of the 236 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. THLD: 1.45 )
Ranked among companies with meaningful PE(NRI) only.
THLD' s PE(NRI) Range Over the Past 10 Years
Min: 0.45  Med: 2.5 Max: 55.56
Current: 1.45
0.45
55.56
P/B 2.31
THLD's P/B is ranked higher than
70% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. THLD: 2.31 )
Ranked among companies with meaningful P/B only.
THLD' s P/B Range Over the Past 10 Years
Min: 0.23  Med: 2.33 Max: 66.81
Current: 2.31
0.23
66.81
P/S 0.97
THLD's P/S is ranked higher than
95% of the 681 Companies
in the Global Biotechnology industry.

( Industry Median: 11.12 vs. THLD: 0.97 )
Ranked among companies with meaningful P/S only.
THLD' s P/S Range Over the Past 10 Years
Min: 0.23  Med: 31.21 Max: 6080
Current: 0.97
0.23
6080
EV-to-EBIT 1.02
THLD's EV-to-EBIT is ranked higher than
90% of the 241 Companies
in the Global Biotechnology industry.

( Industry Median: 23.40 vs. THLD: 1.02 )
Ranked among companies with meaningful EV-to-EBIT only.
THLD' s EV-to-EBIT Range Over the Past 10 Years
Min: -22.4  Med: -1 Max: 39.3
Current: 1.02
-22.4
39.3
EV-to-EBITDA 1.02
THLD's EV-to-EBITDA is ranked higher than
91% of the 264 Companies
in the Global Biotechnology industry.

( Industry Median: 20.40 vs. THLD: 1.02 )
Ranked among companies with meaningful EV-to-EBITDA only.
THLD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -23.3  Med: -1 Max: 37.5
Current: 1.02
-23.3
37.5
Current Ratio 6.19
THLD's Current Ratio is ranked higher than
60% of the 915 Companies
in the Global Biotechnology industry.

( Industry Median: 4.28 vs. THLD: 6.19 )
Ranked among companies with meaningful Current Ratio only.
THLD' s Current Ratio Range Over the Past 10 Years
Min: 1.48  Med: 5.1 Max: 13.48
Current: 6.19
1.48
13.48
Quick Ratio 6.19
THLD's Quick Ratio is ranked higher than
62% of the 915 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. THLD: 6.19 )
Ranked among companies with meaningful Quick Ratio only.
THLD' s Quick Ratio Range Over the Past 10 Years
Min: 1.48  Med: 5.1 Max: 13.48
Current: 6.19
1.48
13.48
Days Sales Outstanding 4.59
THLD's Days Sales Outstanding is ranked higher than
92% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.43 vs. THLD: 4.59 )
Ranked among companies with meaningful Days Sales Outstanding only.
THLD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.59  Med: 354.13 Max: 972.69
Current: 4.59
4.59
972.69

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -8.20
THLD's 3-Year Average Share Buyback Ratio is ranked higher than
58% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. THLD: -8.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
THLD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -702.9  Med: -47.8 Max: -8.2
Current: -8.2
-702.9
-8.2

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.60
THLD's Price/Net Cash is ranked higher than
81% of the 515 Companies
in the Global Biotechnology industry.

( Industry Median: 5.90 vs. THLD: 2.60 )
Ranked among companies with meaningful Price/Net Cash only.
THLD' s Price/Net Cash Range Over the Past 10 Years
Min: 0.45  Med: 2.92 Max: 24.4
Current: 2.6
0.45
24.4
Price/Net Current Asset Value 2.39
THLD's Price/Net Current Asset Value is ranked higher than
83% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 5.50 vs. THLD: 2.39 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
THLD' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.44  Med: 2.81 Max: 24.4
Current: 2.39
0.44
24.4
Price/Tangible Book 2.33
THLD's Price/Tangible Book is ranked higher than
76% of the 764 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. THLD: 2.33 )
Ranked among companies with meaningful Price/Tangible Book only.
THLD' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.4  Med: 2.51 Max: 13.41
Current: 2.33
0.4
13.41
Price/Median PS Value 0.03
THLD's Price/Median PS Value is ranked higher than
99% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. THLD: 0.03 )
Ranked among companies with meaningful Price/Median PS Value only.
THLD' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.01  Med: 0.71 Max: 46.32
Current: 0.03
0.01
46.32
Price/Graham Number 0.39
THLD's Price/Graham Number is ranked higher than
96% of the 181 Companies
in the Global Biotechnology industry.

( Industry Median: 2.92 vs. THLD: 0.39 )
Ranked among companies with meaningful Price/Graham Number only.
THLD' s Price/Graham Number Range Over the Past 10 Years
Min: 0.18  Med: 0.28 Max: 1.68
Current: 0.39
0.18
1.68
Earnings Yield (Greenblatt) (%) 99.91
THLD's Earnings Yield (Greenblatt) (%) is ranked higher than
97% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. THLD: 99.91 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
THLD' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.5  Med: 292.15 Max: 163390.7
Current: 99.91
2.5
163390.7

More Statistics

Revenue (TTM) (Mil) $73.23
EPS (TTM) $ 0.61
Beta2.93
Short Percentage of Float0.44%
52-Week Range $0.21 - 5.28
Shares Outstanding (Mil)71.51

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $)
EPS ($) -0.24 -0.31 0.52
EPS w/o NRI ($) -0.24 -0.31 0.52
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for THLD

Headlines

Articles On GuruFocus.com
Tuesday Pre-Market Insights: THLD, PLL, AOL, CALL May 12 2015 
Threshold Pharmaceuticals Inc. (THLD) CEO Harold E Selick buys 47,619 Shares Mar 15 2011 
Threshold Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 04 2010 
Threshold Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 05 2010 
Threshold Pharmaceuticals Inc. Reports Operating Results (10-Q) May 06 2010 
Threshold Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 05 2009 
Threshold Pharmaceuticals Inc. (THLD) CEO Harold E Selick buys 52,356 Shares Oct 06 2009 
Threshold Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2009 
Threshold Pharmaceuticals Inc. (THLD) CEO Harold E Selick buys 20,000 Shares Jun 05 2009 
Threshold Pharmaceuticals Inc. Reports Operating Results (10-Q) May 07 2009 

More From Other Websites
One Reason Why Threshold Pharma (THLD) Stock Is Jumping Today Aug 22 2016
THRESHOLD PHARMACEUTICALS INC Financials Aug 06 2016
Threshold Pharmaceuticals Reports Second Quarter Financial Results Aug 01 2016
THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 01 2016
Threshold Pharmaceuticals posts 2Q loss Aug 01 2016
Threshold Pharmaceuticals posts 2Q loss Aug 01 2016
Threshold Pharmaceuticals Reports Second Quarter Financial Results Aug 01 2016
THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a... Jul 20 2016
THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security... Jun 27 2016
Most Popular Healthcare Penny Stocks Among Hedge Funds Jun 09 2016
Threshold Pharmaceuticals Highlights Multiple Presentations at the 2016 ASCO Annual Meeting Jun 06 2016
Threshold Pharmaceuticals Highlights Multiple Presentations at the 2016 ASCO Annual Meeting Jun 06 2016
THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Other Events Jun 06 2016
Threshold Pharmaceuticals to Present at Jefferies 2016 Healthcare Conference Jun 01 2016
Threshold Pharmaceuticals to Present at Jefferies 2016 Healthcare Conference Jun 01 2016
Threshold Pharmaceuticals posts 1Q loss May 05 2016
Threshold Pharmaceuticals posts 1Q loss May 05 2016
THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... May 05 2016
Threshold Pharmaceuticals Reports First Quarter Financial Results May 05 2016
ETF’s with exposure to Threshold Pharmaceuticals, Inc. : April 29, 2016 Apr 29 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)